Boruta D M, Schorge J O, Duska L A, Crum C P, Castrillon D H, Sheets E E
Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.
Gynecol Oncol. 2001 Apr;81(1):82-7. doi: 10.1006/gyno.2000.6118.
Patients with early-stage neuroendocrine cervical carcinoma (NECC) have a high mortality rate despite aggressive therapy. The rarity of this tumor precludes initiation of a randomized, prospective trial. We reviewed our experience in early stage disease and performed a meta-analysis of the literature to identify prognostic factors and determine optimal multimodality therapy.
Eleven women with International Federation of Gynecology and Obstetrics (FIGO) early stage (IB--IIA) NECC were treated with surgery and chemotherapy at our institutions between 1978 and 1998. Administration of radiation therapy was recorded, but not required for inclusion in this study. A gynecologic pathologist reviewed all histopathologic sections. Medical records were retrospectively reviewed and clinical data obtained. Twenty-three early-stage NECC patients who were similarly treated during the study interval were identified by a Medline search of the English literature and included in the analysis. The Kaplan--Meier method and log-rank test were used for survival analysis.
The overall 2-year survival rate for the 34 patients was 38%. The median age was 37 years (range, 20--75 years). Median cervical tumor diameter was 3.2 cm (range 0.5--11.0 cm). Lymphovascular space invasion was present in 21 (78%) of 27 patients (7 unknown). Fifteen (52%) of twenty-nine had lymph node metastases (5 unknown). Fifteen patients received postoperative platinum/etoposide (PE), seven received vincristine/adriamycin/cyclophosphamide (VAC), two received alternating cycles of VAC and PE, and ten received other chemotherapy regimens. Twenty women were treated with radiation therapy. The presence of lymph node metastases was a poor prognostic factor (P < 0.001). PE and VAC chemotherapy was associated with increased survival (P < 0.01).
NECC is a highly lethal variant of cervical cancer. The presence of lymph node metastases is the most important prognostic variable. Postoperative VAC or PE appears most likely to improve chances for survival.
尽管采用了积极的治疗方法,早期神经内分泌宫颈癌(NECC)患者的死亡率仍很高。这种肿瘤的罕见性使得无法开展随机前瞻性试验。我们回顾了我们在早期疾病方面的经验,并对文献进行了荟萃分析,以确定预后因素并确定最佳的多模式治疗方法。
1978年至1998年间,我们机构对11例国际妇产科联盟(FIGO)早期(IB-IIA)NECC患者进行了手术和化疗。记录了放疗的使用情况,但本研究纳入标准不要求必须进行放疗。一名妇科病理学家对所有组织病理学切片进行了复查。对病历进行了回顾性审查并获取了临床数据。通过对英文文献进行Medline检索,确定了23例在研究期间接受类似治疗的早期NECC患者,并纳入分析。采用Kaplan-Meier方法和对数秩检验进行生存分析。
34例患者的总体2年生存率为38%。中位年龄为37岁(范围20-75岁)。宫颈肿瘤中位直径为3.2 cm(范围0.5-11.0 cm)。27例患者中有21例(78%)存在淋巴管间隙浸润(7例情况不明)。29例中有15例(52%)有淋巴结转移(5例情况不明)。15例患者接受了术后铂/依托泊苷(PE)治疗,7例接受了长春新碱/阿霉素/环磷酰胺(VAC)治疗,2例接受了VAC和PE交替周期治疗,10例接受了其他化疗方案。20例患者接受了放疗。淋巴结转移的存在是一个不良预后因素(P<0.001)。PE和VAC化疗与生存率提高相关(P<0.01)。
NECC是宫颈癌的一种高致死性变体。淋巴结转移的存在是最重要的预后变量。术后VAC或PE似乎最有可能提高生存机会。